On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009.  Nonetheless, at the start of the year...
Read More »

In our August 2009 article titled “Treating Parkinson’s Disease: Investment Opportunities and Challenges,” we reviewed some of the historical challenges associated with developing treatments for Parkinson’s disease and cited reasons for optimism going forward in addition to highlighting several promising companies making progress. Since that time, many of the companies we featured have...
Read More »

Parkinson’s disease is one of the most common of the neurogenerative diseases affecting 1 in 100 people over the age of 60.  Approximately 1.5 million Americans currently suffer from the disease and it is estimated that 60,000 Americans are newly diagnosed each year.  PD is both a chronic and progressive disease. While the...
Read More »